相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab
Shubham Pant et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival
Alessandra De Remigis et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Jae Yun Lim et al.
CANCER RESEARCH AND TREATMENT (2015)
Dual Blockade of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor-1 Signaling in Metastatic Pancreatic Cancer Phase Ib and Randomized Phase II Trial of Gemcitabine, Erlotinib, and Cixutumumab Versus Gemcitabine Plus Erlotinib (SWOG S0727)
Philip A. Philip et al.
CANCER (2014)
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
T. Dragovich et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells
M. R. Moniri et al.
CANCER GENE THERAPY (2014)
Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
Masanori Kobayashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
Christian Bauer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells
He Ren et al.
CANCER LETTERS (2014)
Hypoxia-Inducible Factor-1 Promotes Pancreatic Ductal Adenocarcinoma Invasion and Metastasis by Activating Transcription of the Actin-Bundling Protein Fascin
Xiao Zhao et al.
CANCER RESEARCH (2014)
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
Stefano Cascinu et al.
DIGESTIVE AND LIVER DISEASE (2014)
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
D. J. Renouf et al.
EUROPEAN JOURNAL OF CANCER (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study
D. J. Watkins et al.
EUROPEAN JOURNAL OF CANCER (2014)
Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells
Qingshan Pei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Myo- inositol trispyrophosphate- mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy
Zahary Raykov et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer
E. Gabriela Chiorean et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
INVESTIGATIONAL NEW DRUGS (2014)
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Peter J. Hosein et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
O. E. Rahma et al.
ANNALS OF ONCOLOGY (2013)
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)
H. Fensterer et al.
ANNALS OF ONCOLOGY (2013)
Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Deniz A. Ucar et al.
Anti-Cancer Agents in Medicinal Chemistry (2013)
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
Nikolaos Ioannou et al.
BMC CANCER (2013)
IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer
Toshiki Hirakawa et al.
BMC CANCER (2013)
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
R. Alvarez et al.
BRITISH JOURNAL OF CANCER (2013)
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer
Shinichi Yabuuchi et al.
CANCER LETTERS (2013)
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
Amir Avan et al.
CANCER RESEARCH (2013)
Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Ian McCaffery et al.
CLINICAL CANCER RESEARCH (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
Amir Avan et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer
Joseph M. Herman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
EGFR and HER2 inhibition in pancreatic cancer
Naomi Walsh et al.
INVESTIGATIONAL NEW DRUGS (2013)
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Stefan Boeck et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis
Wei Tian et al.
PANCREATOLOGY (2013)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
C. Hage et al.
CELL DEATH & DISEASE (2013)
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
H. L. Kindler et al.
ANNALS OF ONCOLOGY (2012)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
J. Harder et al.
BRITISH JOURNAL OF CANCER (2012)
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Christine M. Ardito et al.
CANCER CELL (2012)
A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
Yefei Rong et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2012)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
Yukino Kimura et al.
PANCREAS (2012)
Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment
Bin Bao et al.
PLOS ONE (2012)
Prognostic MicroRNAs in Cancer Tissue from Patients Operated for Pancreatic Cancer-Five MicroRNAs in a Prognostic Index
Nicolai A. Schultz et al.
WORLD JOURNAL OF SURGERY (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Ghassan K. Abou-Alfa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
Eric Lutz et al.
ANNALS OF SURGERY (2011)
Bcl-2 Upregulation Induced by miR-21 Via a Direct Interaction Is Associated with Apoptosis and Chemoresistance in MIA PaCa-2 Pancreatic Cancer Cells
Jie Dong et al.
ARCHIVES OF MEDICAL RESEARCH (2011)
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
J. Feliu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model
Hidenobu Ishizaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Else M. Inderberg Suso et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells
Victoria Sung et al.
CANCER SCIENCE (2011)
Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway
Sonyo Shin-Kang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
Chenwei Li et al.
GASTROENTEROLOGY (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Synne Weden et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study
Donald A. Richards et al.
INVESTIGATIONAL NEW DRUGS (2011)
MicroRNA-196: critical roles and clinical applications in development and cancer
Changyi Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
Effects and Mechanisms of the Combination of Suberoylanilide Hydroxamic Acid and Bortezomib on the Anticancer Property of Gemcitabine in Pancreatic Cancer
Jun Kyu Lee et al.
PANCREAS (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer National Cancer Institute of Canada Clinical Trials Group Study PA 3
Gilda da Cunha Santos et al.
CANCER (2010)
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
Andrew H. Ko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Shuangni Yu et al.
CANCER RESEARCH (2010)
miR-146a Suppresses Invasion of Pancreatic Cancer Cells
Yiwei Li et al.
CANCER RESEARCH (2010)
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa et al.
CANCER SCIENCE (2010)
The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS
Wu-Gan Zhao et al.
CARCINOGENESIS (2010)
Immunotherapy of Malignant Disease with Tumor Antigen-Specific Monoclonal Antibodies
Michael Campoli et al.
CLINICAL CANCER RESEARCH (2010)
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment
Shannon Kidd et al.
CYTOTHERAPY (2010)
MicroRNA-20a Overexpression Inhibited Proliferation and Metastasis of Pancreatic Carcinoma Cells
Haijiao Yan et al.
HUMAN GENE THERAPY (2010)
Intravenous administration of ReolysinA®, a live replication competent RNA virus is safe in patients with advanced solid tumors
Radharani Gollamudi et al.
INVESTIGATIONAL NEW DRUGS (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells
Amit Deorukhkar et al.
PANCREAS (2010)
Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer
Jin-Hyeok Hwang et al.
PLOS ONE (2010)
TGFβ signalling: a complex web in cancer progression
Hiroaki Ikushima et al.
NATURE REVIEWS CANCER (2010)
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia
Nils Habbe et al.
CANCER BIOLOGY & THERAPY (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Notch Signaling: The Core Pathway and Its Posttranslational Regulation
Mark E. Fortini
DEVELOPMENTAL CELL (2009)
let-7 MicroRNA Transfer in Pancreatic Cancer-Derived Cells Inhibits In Vitro Cell Proliferation but Fails to Alter Tumor Progression
Jerme Torrisani et al.
HUMAN GENE THERAPY (2009)
Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance
Taiki Moriyama et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The Hedgehog Pathway and Pancreatic Cancer
Manuel Hidalgo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Joanna M. Brell et al.
ONCOLOGY (2009)
A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer
Yoshiki Hirooka et al.
PANCREAS (2009)
Antisense Inhibition of microRNA-21 or-221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma
Jong-Kook Park et al.
PANCREAS (2009)
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Qing Ji et al.
PLOS ONE (2009)
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Masahiro Seike et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
Neil Desai et al.
TRANSLATIONAL ONCOLOGY (2009)
Microenvironmental regulation of metastasis
Johanna A. Joyce et al.
NATURE REVIEWS CANCER (2009)
Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells
Shayna L. Showalter et al.
CANCER BIOLOGY & THERAPY (2008)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival
Mary Dillhoff et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells
Bryan P. Toole et al.
SEMINARS IN CANCER BIOLOGY (2008)
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
Robert G. Maki et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models
Xiaoming Xie et al.
CANCER CELL (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer
Nichole Boyer Arnold et al.
CLINICAL CANCER RESEARCH (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo
J Schmidt et al.
CANCER (2006)
Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes
GR Rossi et al.
CANCER RESEARCH (2005)
Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes
GR Rossi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Assessment of HER-2 status in pancreatic adenocarcinoma - Correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival
AJ Saxby et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Identification of novel human CTL Epitopes and their agonist epitopes of mesothelin
J Yokokawa et al.
CLINICAL CANCER RESEARCH (2005)
Immunization with mutant p53- and K-ras-derived peptides in cancer patients:: Immune response and clinical outcome
DP Carbone et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
RK Ramanathan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
JP Neoptolemos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
MA Morse et al.
JOURNAL OF GASTROINTESTINAL CANCER (2002)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
